Trials / No Longer Available
No Longer AvailableNCT02082691
Continued Administration of G-202 for One Patient With Advanced Hepatocellular Carcinoma
Single Patient IND: Continued Administration of G-202 to a Patient With Advanced Hepatocellular Carcinoma Previously Treated With G-202 and Receiving Clinical Benefit
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Devalingam Mahalingam · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Patient with advanced liver cancer (cancer that has spread to other parts of the body) continues to receive the study drug (G-202) even though patient no longer meets the criteria to be a part of the main treatment study. Patient's cancer responded well to receiving G-202 in the main study and will receive G-202 at the same dose given in the main study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | G-202 | Patient will receive G-202 for 3 days in a row, followed by 25 days without taking G-202. This cycle will be repeated every 28 days. Patient will receive G-202 as long as his/her cancer does not grow and the investigational drug side effects are tolerable. |
Timeline
- First posted
- 2014-03-10
- Last updated
- 2014-03-10
Source: ClinicalTrials.gov record NCT02082691. Inclusion in this directory is not an endorsement.